Literature DB >> 2403300

Microalbuminuria. Potential marker for increased cardiovascular risk factors in nondiabetic subjects?

S M Haffner1, M P Stern, M K Gruber, H P Hazuda, B D Mitchell, J K Patterson.   

Abstract

Microalbuminuria is associated with progression to renal disease in insulin-dependent diabetes and with increased mortality in noninsulin-dependent diabetes. In contrast, few studies have addressed the effect of microalbuminuria on cardiovascular risk in nondiabetics. We, therefore, determined the level of microalbuminuria in 316 nondiabetic subjects from the San Antonio Heart Study, a population-based study of diabetes and cardiovascular risk factors. Microalbuminuria (greater than or equal to 30 mg/l) was found in 42 of these 316 subjects (13%). Subjects with microalbuminuria had significantly higher blood pressure, triglyceride concentration, sum of insulin concentrations during a glucose tolerance test, and prevalence of hypertension and of self-reported myocardial infarction than subjects without microalbuminuria. When subjects with hypertension were excluded (n = 27), normotensive subjects with microalbuminuria (n = 31) still had significantly higher triglyceride concentrations and insulin sum than normotensive subjects without microalbuminuria (n = 258), suggesting that an increased atherogenic risk factor pattern exists even in normotensive subjects with microalbuminuria. Microalbuminuria may be a marker for cardiovascular risk, although it is not certain whether microalbuminuria causes these metabolic changes or results from some metabolic disturbance such as insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403300     DOI: 10.1161/01.atv.10.5.727

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  33 in total

1.  Microalbuminuria.

Authors:  P H Winocour
Journal:  BMJ       Date:  1992-05-09

2.  Albumin excretion rate levels in non-diabetic offspring of NIDDM patients with and without nephropathy.

Authors:  G Gruden; P Cavallo-Perin; C Olivetti; E Repetti; R Sivieri; A Bruno; G Pagano
Journal:  Diabetologia       Date:  1995-10       Impact factor: 10.122

3.  Proteinuria and metabolic syndrome as predictors of cardiovascular death in non-diabetic and type 2 diabetic men and women.

Authors:  A Juutilainen; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  Diabetologia       Date:  2005-12-20       Impact factor: 10.122

Review 4.  Treatment of patients with essential hypertension and microalbuminuria.

Authors:  J Redon
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

5.  A 100-kDa urinary protein is associated with insulin resistance in offspring of type 2 diabetic patients.

Authors:  A Pätäri; P Karhapää; H Taipale; U Salmenniemi; E Ruotsalainen; P Vanninen; H Holthöfer; M Laakso
Journal:  Diabetologia       Date:  2005-07-08       Impact factor: 10.122

Review 6.  Paper-based assays for urine analysis.

Authors:  Eric Lepowsky; Fariba Ghaderinezhad; Stephanie Knowlton; Savas Tasoglu
Journal:  Biomicrofluidics       Date:  2017-10-17       Impact factor: 2.800

7.  Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects--evidence against a modulating role for insulin.

Authors:  V Mohamed-Ali; M M Gould; S Gillies; S Goubet; J S Yudkin; A P Haines
Journal:  Diabetologia       Date:  1995-09       Impact factor: 10.122

8.  Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India.

Authors:  A Varghese; R Deepa; M Rema; V Mohan
Journal:  Postgrad Med J       Date:  2001-06       Impact factor: 2.401

9.  Insulin resistance and abnormal albumin excretion in non-diabetic first-degree relatives of patients with NIDDM.

Authors:  C M Forsblom; J G Eriksson; A V Ekstrand; A M Teppo; M R Taskinen; L C Groop
Journal:  Diabetologia       Date:  1995-03       Impact factor: 10.122

10.  Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  L Groop; A Ekstrand; C Forsblom; E Widén; P H Groop; A M Teppo; J Eriksson
Journal:  Diabetologia       Date:  1993-07       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.